CliffBio
small molecule

LUMIGAN

BIMATOPROST

Loss of exclusivityJune 2027latest FDA-listed patent expiry
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameLUMIGAN
Active ingredientBIMATOPROST
Strength0.01%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalAugust 2010
Marketing statusRX

Listed patents

PatentExpiresType
7851504June 2027substance, product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LUMIGAN patent cliff — loss of exclusivity June 2027 | CliffBio